Bone marrow necrosis associated with the use of imatinib mesylate in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia

Ann Hematol. 2006 Aug;85(8):542-4. doi: 10.1007/s00277-005-0071-3. Epub 2006 Mar 29.

Authors

Kosei Matsue, Masami Takeuchi, Mihoko Koseki, Hidetaka Uryu

PMID: 16570152
DOI: 10.1007/s00277-005-0071-3

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects*
Benzamides
Bone Marrow / pathology
Bone Marrow Diseases / blood
Bone Marrow Diseases / chemically induced*
Bone Marrow Diseases / pathology*
Humans
Imatinib Mesylate
Male
Necrosis / chemically induced
Necrosis / pathology
Piperazines / administration & dosage
Piperazines / adverse effects*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood
Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
Pyrimidines / administration & dosage
Pyrimidines / adverse effects*

Substances

Antineoplastic Agents
Benzamides
Piperazines
Pyrimidines
Imatinib Mesylate